Novartis’s Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in advanced or mBC patients

 Novartis’s Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in advanced or mBC patients

Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B

Shots:
  •  In a global P-III combination of BYL719 + fulvestrant improved PFS vs fulvestrant in postmenopausal women and men with (HR+/HER2-) PIK3CA-mutant Breast Cancer that progressed on aromatase inh. ± CDK4/6i
  •  In this study (N=572) in ratio 1:1 BYL719 300 mg (P.O.) + fulvestrant 500mg (IM QD) in patients either in PIK3CA-mutant cohort or PIK3CA non-mutant cohort
  • Novartis is expected to present complete results in upcoming congress and initiate WW regulatory discussions

Click here to read full press release/ article | Ref: Novartis | Image: Novartis

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post